Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France

被引：0
|
作者：
Perol, M. [1 ]
Filleron, T. [2 ]
Quantin, X. [3 ]
Chouaid, C. [4 ]
Valette, C. Audigier [5 ]
Lena, H. [6 ]
Kaderbhai, C. [7 ]
Fabre, C. [8 ]
Santorelli, M. [9 ]
Bensimon, L. [10 ]
Burke, T. [11 ]
Couch, D. [12 ]
Nguyen, E. [12 ]
Courtinard, C. [12 ]
机构：
[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[2] Ctr Claudius Regaud, Biostat, Toulouse, France
[3] ICM Reg Canc Inst Montpellier, Montpellier, France
[4] CH Intercommunal Creteil, Creteil, France
[5] Hop St Musse, Toulon, France
[6] CHU Pontchaillou, Rennes, France
[7] Ctr Georges Francois Leclerc, Dijon, France
[8] IQVIA Co France, Capionis, Courbevoie, France
[9] Merck & Co Inc, Rahway, NJ USA
[10] MSD France, Dir Ass Evaluat Med Econ & Epidemiol, Puteaux La Defense, France
[11] Merck & Co Inc, Kenilworth, NJ USA
[12] UNICANCER, Data Off, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
109P
引用
收藏
页码：S757 / S758
页数：2
相关论文
共 50 条
  • [31] Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy
    Julian, C.
    Machado, R.
    Girish, S.
    Chanu, P.
    Heinzmann, D.
    Harbron, C.
    Gershon, A.
    Pfeiffer, S.
    Zou, W.
    Quarmby, V.
    Zhang, Q.
    Chen, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S644 - S644
  • [32] Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low
    Attili, I.
    Valenza, C.
    Santoro, C.
    Antonarelli, G.
    Aliaga, P. Trillo
    Del Signore, E.
    Catania, C.
    Spitaleri, G.
    Passaro, A.
    de Marinis, F.
    ANNALS OF ONCOLOGY, 2022, 33 : S51 - S51
  • [33] Real-world adoption of PD-L1 testing in metastatic urothelial carcinoma.
    Gupta, Shilpa
    Maculaitis, Martine C.
    Bernstein, Andrew
    Boudoures, Anna
    Tesic-Schnell, Marija
    Seal, Brian S.
    Mulvihill, Emily
    Doleh, Yunes
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
    Rittberg, Rebekah
    Leung, Bonnie
    Shokoohi, Aria
    Pender, Alexandra
    Wong, Selina
    Al-Hashami, Zamzam
    Wang, Ying
    Ho, Cheryl
    CURRENT ONCOLOGY, 2023, 30 (06) : 5299 - 5308
  • [35] Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
    Jones, Lauren
    Rittberg, Rebekah
    Leung, Bonnie
    Shokoohi, Aria
    Pender, Alexandra
    Wong, Selina
    Al-Hashami, Zamzam
    Wang, Ying
    Ho, Cheryl
    CURRENT ONCOLOGY, 2022, 29 (11) : 8686 - 8692
  • [36] First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices
    Velcheti, V.
    Chandwani, S.
    Chen, X.
    Pietanza, M. C.
    Burke, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 18 - 18
  • [37] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [38] Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001)
    Kitamura, Yasuo
    Mizugaki, Hidenori
    Ikezawa, Yasuyuki
    Morita, Ryo
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Furuta, Megumi
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Oizumi, Satoshi
    ANNALS OF ONCOLOGY, 2022, 33 : S524 - S524
  • [39] Real-world data of first-line treatment with pembrolizumab for highly PD-L1 expressing NSCLC (HOT/NJLCG2001)
    Nakamura, A.
    Mizugaki, H.
    Ikezawa, Y.
    Morita, R.
    Tateishi, K.
    Yokoo, K.
    Sumi, T.
    Kikuchi, H.
    Kitamura, Y.
    Morita, M.
    Aso, M.
    Tsukita, Y.
    Yoshiike, F.
    Furuta, M.
    Tanaka, H.
    Sekikawa, M.
    Hachiya, T.
    Nakamura, K.
    Yokouchi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1008
  • [40] Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids
    Frost, Nikolaj
    Kollmeier, Jens
    Misch, Daniel
    Vollbrecht, Claudia
    Grah, Christian
    Matthes, Burkhard
    Pultermann, Dennis
    Olive, Elisabeth
    Raspe, Matthias
    Ochsenreither, Sebastian
    von Laffert, Maximilian
    Suttorp, Norbert
    Witzenrath, Martin
    Grohe, Christian
    CLINICAL LUNG CANCER, 2021, 22 (05) : 411 - 422
12345